Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation
- 1 September 2006
- journal article
- Published by Wiley in Microcirculation
- Vol. 13 (6) , 489-497
Abstract
Objective: Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation and activation of the coagulation system. Since these biologies likely underlie development of vascular disease in sickle subjects, they offer attractive targets for novel therapeutics. Similar findings characterize the sickle transgenic mouse, which therefore provides a clinically relevant inflammation model.Method: The authors tested two polyhydroxyphenyl hydroxamic acid derivatives, didox and trimidox, in sickle transgenic mice. Animals were examined by intravital microscopy (cremaster muscle and dorsal skin fold preparations) and by histochemistry before and after transient exposure to hypoxia, with versus without preadministration of study drug. Previous studies have validated the application of hypoxia/reoxygenation to sickle transgenic mice as a disease‐relevant model.Results: Animals pretreated with these agents exhibited marked improvements in leukocyte/ endothelial interaction, hemodynamics and vascular stasis, and endothelial tissue factor expression. Thus, these drugs unexpectedly exert powerful inhibition on both the inflammation and coagulation systems.Conclusions: Each of these changes is expected to be therapeutically beneficial in systemic inflammatory disease in general, and in sickle disease in particular. Thus, these novel compounds offer the advantage of having multiple therapeutic benefits in a single agent.Keywords
This publication has 35 references indexed in Scilit:
- Iron nitrosyl hemoglobin formation from the reaction of hydroxylamine and hemoglobin under physiological conditionsBiochimica et Biophysica Acta (BBA) - General Subjects, 2004
- Coagulation in SepsisThe American Journal of the Medical Sciences, 2004
- Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatinBlood, 2004
- Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic VasculopathyMicrocirculation, 2004
- Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didoxAntiviral Research, 2002
- Efficacy of a hydroxyl radical scavenger (VF 233) in preventing reperfusion injury in the isolated rabbit heartThe Annals of Thoracic Surgery, 1992
- In vivo and in vitro measurements of red cell velocity under epifluorescence microscopyMicrovascular Research, 1989
- In vivo measurements of “apparent viscosity” and microvessel hematocrit in the mesentery of the catMicrovascular Research, 1980
- The correlation of photometric signals derived from in vivo red blood cell flow in microvesselsMicrovascular Research, 1974